American pharma giants are increasingly turning to Chinese labs to discover, test and develop cutting-edge drugs.
On today’s Big Take Asia podcast, Bloomberg’s Amber Tong and Robert Langreth join Oanh Ha to break down why global drugmakers are sourcing their next big breakthroughs from China — and what that means for US biotech dominance.
Read more: Big Pharma Is Hooked on Chinese Licensing Deals
Hosted by K. Oanh Ha; Produced by Naomi Ng and David Fox; Guests: Amber Tong and Robert Langreth; Edited by Paddy Hirsch and Crispina Robert.
Fact-checking by Brunella Tipismana Urbano; Engineering by Alex Suguira.
Senior Producer: Naomi Shavin; Deputy Executive Producer: Julia Weaver. Executive Producer: Nicole Beemsterboer.

How India Is Training the Robots of the Future
17:50

How Two-Minute Microdramas Became a Billion-Dollar Industry
20:11

The Chinese AI Model Rattling Silicon Valley and Washington
17:34